CorriXR Therapeutics
Manufacturing · Delaware, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
550 S College Ave Ste 107, Newark, Delaw...Website
www.corrixr.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About CorriXR Therapeutics
CorriXR Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR/Cas gene editing therapies to overcome drug resistance in solid tumors. Its lead candidate, CXR101, targets the NRF2 pathway in squamous cell carcinomas, aiming to enhance treatment response and improve patient outcomes through precise, tumor-localized delivery.Explore more
CorriXR Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is CorriXR Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if CorriXR Therapeutics had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
CorriXR Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if CorriXR Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if CorriXR Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once CorriXR Therapeutics has new funding data
Product Launch: Get notified when CorriXR Therapeutics launches new products
Earning: See what the market has to say on CorriXR Therapeutics recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at CorriXR Therapeutics
Recommended Actions
Reach out to Masked Content who joined CorriXR Therapeutics as Masked Content
Find 3 more new buyers
Compare Similar Companies to CorriXR Therapeutics
Compare insights from companies similar to CorriXR Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
CorriXR Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
CorriXR Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about CorriXR Therapeutics.
CorriXR Therapeutics Tech Stack
A closer look at the technologies used by CorriXR Therapeutics
Most Recent Scoops
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
New Hire
Executive Move
Executive Moves, New Hire
Left Company
Executive Move
Executive Moves, Left Company, Board of Directors
Promotion
Executive Move
Executive Moves, Promotion
Event
Person-Based
Events, Search, Medical Research
CorriXR Therapeutics News & Media
CorriXR Therapeutics Names Eric Kmiec Chief Executive Officer
NEWARK, Del.--(BUSINESS WIRE)-- #CRISPR--CorriXR Therapeutics, Inc., a leading biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, has announced that Eric B. Kmiec, Ph.D., the company's founder and chief scientific officer, will assume the role of chief executive officer. "We are confident that Eric’s exceptional leadership will drive CorriXR forward in its mission to develop transformative treatments,” said Janice Nevin, M.D., MPHCitizens Bank of Edmond CEO joins CorriXR Board of Directors | The Journal Record
Citizens Bank of Edmond CEO Jill Castilla is the newest appointment to a biotherapeutics company’s board of directors.CorriXR Therapeutics Appoints Jill Castilla to Its Board of Directors
OKLAHOMA CITY--(BUSINESS WIRE)-- #CRISPR--CorriXR Therapeutics, Inc. (“CorriXR”), a biotherapeutics company developing unique genetic medicines that optimize the effectiveness of existing cancer treatments by knocking out genes responsible for resistance, today announced the appointment of Jill Castilla to its Board of Directors. Ms. Castilla brings visionary leadership as a nationally recognized innovator in finance and banking. “We are very pleased to welcome Jill to our Board and believe sheCorriXR: Oncology-Focused Biotherapeutics Development Company Raises Funding
Cortado Ventures - a leading investment firm committed to supporting innovation and growth - announced a strategic investment in CorriXR Therapeutics, an oncology-focused biotherapeutics development company with a pioneering gene editing platform technology. And this investment solidifies Cortado's commitment to advancing cutting-edge medical solutions and supporting the development of groundbreaking treatments for cancer.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding CorriXR Therapeutics
Sign Up For FreeTo access detailed company insights
CorriXR Therapeutics is a clinical-stage biotechnology company developing in vivo CRISPR/Cas gene editing therapies to overcome drug resistance in solid tumors. Its lead candidate, CXR101, targets the NRF2 pathway in squamous cell carcinomas, aiming to enhance treatment response and improve patient outcomes through precise, tumor-localized delivery... Read More
